# US 6,726,925 B1 · Temperature-sensitive liposomal formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,925 B1
- Document ID: US6726925B1
- Status: Granted
- Kind: B1
- Application number: 09/458,484
- Filed: 1999-12-09
- Granted: 2004-04-27
- Earliest claimed: 1998-06-18
- Assignees: Duke University
- Inventors: David Needham
- Web page: https://patentgrep.com/patent/US6726925B1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the percentage of active agent released at the phase transition temperature of the lipid bilayer, compared to that which would occur in the absence of the surface active agent. The surface active agent is present in the lipid bilayer membrane so as to not destabilize the membrane in the gel phase.

## Claims

### Claim 1

A liposome, comprising a gel-phase lipid bilayer membrane having a phase transition temperature, and an active agent,
wherein the gel-phase lipid bilayer membrane comprises:
(a) one or more phospholipids selected from the group consisting of phosphatidyl cholines, phosphatidyl glycerols, phosphatidyl inositols, and phosphatidyl ethanolamines, wherein the one or more phospholipids have two acyl groups; and
(b) one or more lysolipids selected from the group consisting of monoacylphosphatidyl cholines, monoacylphosphatidylglycerols, monoacylphosphatidylinositols, and monoacylphosphatidylethanolamines, wherein the one or more lysolipids have one acyl group; and
wherein the active agent is selected from the group consisting of a pharmacologically active agent or a diagnostic agent; and
wherein the phase transition temperature is 39 to 45° C., and,
wherein the amount of the one or more lysolipids in the gel-phase lipid bilayer membrane is sufficient to increase a first percentage of active agent released from the liposome at the phase transition temperature, compared to a second percentage of active agent released in the absence of the one or more lysolipids.

### Claim 2 (depends on 1)

The liposome of claim 1, wherein the phospholipid and lysolipid are contained in a molar ratio of from 99:1 to 51:49.

### Claim 3 (depends on 1)

The liposome of claim 1, wherein the phospholipid and lysolipid are contained in a molar ratio of from 99:1 to 70:30.

### Claim 4 (depends on 1)

The liposome of claim 1, wherein the acyl groups of the phospholipids are saturated.

### Claim 5 (depends on 1)

The liposome of claim 1, wherein the lysolipid is monopalmitoylphosphatidylcholine (MPPC), monolaurylphosphatidylcholine (MLPC), monomyristoylphosphatidylcholine (MMPC), monostearoylphosphatidylcholine (MSPC), and mixtures thereof.

### Claim 6 (depends on 5)

The liposome of claim 5, wherein the lysolipid is monostearoylphosphatidylcholine (MSPC).

### Claim 7 (depends on 6)

The liposome of claim 6, wherein the lysolipid is monostearoylphosphatidylcholine (MSPC) and the phospholipid is dipalmitoylphosphatidylcholine (DPPC).

### Claim 8 (depends on 5)

The liposome of claim 5, wherein the lysolipid is monopalmitoylphosphatidylcholine (MPPC) and the phospholipid is dipalmitoylphosphatidylcholine (DPPC).

### Claim 9 (depends on 1)

The liposome of claim 1, wherein the active agent is entrapped within the interior of the liposome.

### Claim 10 (depends on 1)

The liposome of claim 1, wherein the active agent is entrapped within the gel-phase lipid bilayer membrane.

### Claim 11 (depends on 1)

The liposome of claim 1, having a diameter of from about 50 nanometers to about 400 nanometers.

### Claim 12 (depends on 1)

The liposome of claim 1, wherein the gel-phase livid bilayer membrane further comprises a phospholipid derivatized with a hydrophilic polymer.

### Claim 13 (depends on 12)

The liposome of claim 12, wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, polyvinyl alcohols, polyvinylpyrrolidone, oligosaccharides, and mixtures thereof.

### Claim 14 (depends on 1)

The liposome of claim 1, wherein the active agent is a pharmacologically active agent selected from the group consisting of anesthetics, antihistamines, antineoplastics anti-ulceratives, anti-seizure agents, muscle relaxants, immunosuppressive agents, anti-infective agents, non-steroidal anti-inflammatory agents, imaging agents, nutritional agents, and mixtures thereof.

### Claim 15 (depends on 14)

The liposome of claim 14, wherein the active agent is selected from the group consisting of antineoplastic agents, non-steroidal anti-inflammatory agents, immunosuppressive agents, and anti-infective agents.

### Claim 16 (depends on 14)

The liposome of claim 14, wherein the active agent is an antihistamine.

### Claim 17 (depends on 14)

The liposome of claim 14, wherein the active agent is an antineoplastic agent or antitumor agent.

### Claim 18 (depends on 14)

The liposome of claim 14, wherein the active agent is selected from the group consisting of methotrexate, doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisone, and navalbene.

### Claim 19 (depends on 18)

The liposome of claim 18, wherein the active agent is paclitaxel.

### Claim 20 (depends on 18)

The liposome of claim 18, wherein the active agent is camptothecin.

### Claim 21 (depends on 18)

The liposome of claim 18, wherein the active agent is doxorubicin.

### Claim 22 (depends on 14)

The liposome of claim 14, wherein the active agent is a non-steroidal anti-inflammatory agent.

### Claim 23 (depends on 22)

The liposome of claim 22, wherein the active agent is ibuprofen.

### Claim 24

A method of administering an active agent to a preselected target site in a subject's body, comprising:
(a) administering a liposome containing the active agent, wherein the liposome comprises a gel-phase lipid bilayer membrane having a phase transition temperature, and an active agent,
wherein the gel-phase lipid bilayer membrane comprises:
(i) one or more phospholipids selected from the group consisting of phosphatidyl cholines, phosphatidyl glycerols, phosphatidyl inositols, and phosphatidyl ethanolamines, wherein the phospholipids have two acyl groups; and
(ii) one or more lysolipids selected from the group consisting of monoacylphosphatidylcholines, monoacylphosphatidylglycerols, monoacylphosphatidylinositols, and monoacylphosphatidylethanolamines, wherein the one or more lysolipids have one acyl group; and
wherein the active agent is selected from the group consisting of a pharmacologically active agent or a diagnostic agent; and
(b) heating the subject's preselected target site to a temperature about 39° C. to 45° C. to release the active agent from the liposome at the target site;
wherein the amount of the one or more lysolipids in the lipid bilayer membrane is sufficient to increase a first percentage of active agent released from the liposome at the phase transition temperature, compared to a second percentage of active agent released in the absence of the one or more lysolipids.

### Claim 25 (depends on 24)

The method of claim 24, wherein the preselected target site comprises a solid tumor.

### Claim 26 (depends on 24)

The method of claim 24, wherein the liposome comprises an antineoplastic agent.

### Claim 27 (depends on 26)

The method of claim 26, wherein the antineoplastic agent is selected from the group consisting of methotrexate, doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisone, and navalbene.

### Claim 28 (depends on 24)

The method of claim 24, wherein the administration of (a) comprises intravenous administration.

### Claim 29 (depends on 24)

The method of claim 24, wherein the acyl groups of the phospholipid are saturated.

### Claim 30 (depends on 24)

The method of claim 24, wherein the phospholipid and lysolipid are contained in a molar ratio of from 99:1 to 50:50.

### Claim 31 (depends on 30)

The method of claim 30, wherein the lysolipid is monopalmitoylphosphatidylcholine (MPPC), monolaurylphosphatidylcholine (MLPC), monomyristoylphosphatidylcholine (MMPC), monostearoylphosphatidylcholine (MSPC), and mixtures thereof.

### Claim 32 (depends on 24)

The method of claim 24, wherein the active agent is entrapped within the interior of the liposome.

### Claim 33 (depends on 24)

The method of claim 24, wherein the active agent is entrapped within the gel-phase lipid bilayer membrane of the liposome.

### Claim 34 (depends on 24)

The method of claim 24, wherein the liposome has a diameter of from about 50 nanometers to about 400 nanometers.

### Claim 35 (depends on 24)

The method of claim 24, wherein the gel-phase lipid bilayer membrane further comprises a phospholipid derivatized with a hydrophilic polymer.

### Claim 36 (depends on 35)

The method of claim 35, wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, polyvinyl alcohols, polyvinylpyrrolidone, oligosaccharides, and mixtures thereof.

### Claim 37 (depends on 24)

The method of claim 24, wherein the active agent is a pharmacologically active agent selected from the group consisting of anesthetics, antihistamines, antineoplastics, anti-ulceratives, anti-seizure agents, muscle relaxants, immunosuppressive agents, anti-infective agents, non-steroidal anti-inflammatory agents, imaging agents, nutritional agents, and mixtures thereof.

### Claim 38 (depends on 37)

The method of claim 37, wherein the active agent is selected from the group consisting of antineoplastic agents, non-steroidal anti-inflammatory agents, immunosuppressive agents, and anti-infective agents.

### Claim 39 (depends on 37)

The method of claim 37, wherein the active agent is an antihistamine.

### Claim 40 (depends on 37)

The method of claim 37, wherein the active agent is a non-steroidal anti-inflammatory agent.

### Claim 41 (depends on 40)

The method of claim 40, wherein the active agent is ibuprofen.

### Claim 42

A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier, and a liposome having a gel-phase lipid bilayer membrane having a phase transition temperature, and an active agent,
wherein the gel-phase lipid bilayer membrane comprises:
(a) one or more phospholipids selected from the group consisting of phosphatidyl cholines, phosphatidyl glycerols, phosphatidyl inositols, and phosphatidyl ethanolamines, wherein the one or more phospholipids have two acyl groups; and
(b) one or more lysolipids selected from the group consisting of monoacylphosphatidylcholines, monoacylphosphatidylglycerols monoacylphosphatidylinositols and monacylphosphatidylethanolamines, wherein the one or more lysolipids have one acyl group; and
wherein the active agent is selected from the group consisting of a pharmacologically active agent or a diagnostic agent; and
wherein the phase transition temperature is 39 to 45° C.; and
wherein the amount of the one or lysolipids in the gel-phase lipid bilayer membrane is sufficient to increase a first percentage of active agent released from the liposome at the phase transition temperature, compared to a second percentage of active agent released in the absence of one or more lysolipids.

### Claim 43 (depends on 42)

The pharmaceutical composition of claim 42, wherein the liposomes are dispersed in an aqueous preparation.

### Claim 44 (depends on 43)

The pharmaceutical composition of claim 43, comprising physiological saline or PBS.

### Claim 45 (depends on 42)

The pharmaceutical composition of claim 42, wherein the phospholipid and lysolipid are contained in a molar ratio of from 99:1 to 51:49.

### Claim 46 (depends on 42)

The pharmaceutical composition of claim 42, wherein the phospholipid and lysolipid are contained in a molar ratio of from 99:1 to 70:30.

### Claim 47 (depends on 42)

The pharmaceutical composition of claim 42, wherein the acyl groups of the phospholipids are saturated.

### Claim 48 (depends on 42)

The pharmaceutical composition of claim 42, wherein the lysolipid is monopalmitoylphosphatidylcholine (MPPC), monolaurylphosphatidylcholine (MLPC), monomyristoylphosphatidylcholine (MMPC), monostearoylphosphatidylcholine (MSPC), and mixtures thereof.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, wherein the lysolipid is monostearoylphosphatidylcholine (MSPC).

### Claim 50 (depends on 49)

The pharmaceutical composition of claim 49, wherein the lysolipid is monostearoylphosphatidylcholine (MSPC) and the phospholipid is dipalmitoylphosphatidylcholine (DPPC).

### Claim 51 (depends on 48)

The pharmaceutical composition of claim 48, wherein the lysolipid is monopalmitoylphosphatidylcholine (MPPC) and the phospholipid is dipalmitoylphosphatidylcholine (DPPC).

### Claim 52 (depends on 42)

The pharmaceutical composition of claim 42, wherein the active agent is entrapped within the interior of the liposome.

### Claim 53 (depends on 42)

The pharmaceutical composition of claim 42, wherein the active agent is entrapped within the gel-phase lipid bilayer membrane.

### Claim 54 (depends on 42)

The pharmaceutical composition of claim 42, wherein the liposome has a diameter of from about 50 nanometers to about 400 nanometers.

### Claim 55 (depends on 42)

The pharmaceutical composition of claim 42, wherein the gel-phase lipid bilayer further comprises a phospholipid derivatized with a hydrophilic polymer.

### Claim 56 (depends on 53)

The pharmaceutical composition of claim 53, wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, polyvinyl alcohols, polyvinylpyrrolidone, oligosaccharides, and mixtures thereof.

### Claim 57 (depends on 42)

The pharmaceutical composition of claim 42, wherein the active agent is a pharmacologically active agent selected from the group consisting of anesthetics, antihistamines, antineoplastics, anti-ulceratives, anti-seizure agents, muscle relaxants, immunosuppressive agents, anti-infective agents, non-steroidal anti-inflammatory agents, imaging agents, nutritional agents, and mixtures thereof.

### Claim 58 (depends on 57)

The pharmaceutical composition of claim 57, wherein the active agent is selected from the group consisting of antineoplastic agents, non-steroidal anti-inflammatory agents, immunosuppressive agents, and anti-infective agents.

### Claim 59 (depends on 57)

The pharmaceutical composition of claim 57, wherein the active agent is an antihistamine.

### Claim 60 (depends on 57)

The pharmaceutical composition of claim 57, wherein the active agent is an antineoplastic agent or antitumor agent.

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60, wherein the active agent is selected from the group consisting of methotrexate, doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisone, and navalbene.

### Claim 62 (depends on 61)

The pharmaceutical composition of claim 61, wherein the active agent is paclitaxel.

### Claim 63 (depends on 61)

The pharmaceutical composition of claim 61, wherein the active agent is camptothecin.

### Claim 64 (depends on 61)

The pharmaceutical composition of claim 61, wherein the active agent is doxorubicin.

### Claim 65 (depends on 57)

The pharmaceutical composition of claim 57, wherein the active agent is a non-steroidal anti-inflammatory agent.

### Claim 66 (depends on 65)

The pharmaceutical composition of claim 65, wherein the active agent is ibuprofen.

### Claim 67 (depends on 1)

The liposome of claim 1, wherein the one or more phospholipids have two C16-C24 acyl groups.

### Claim 68 (depends on 1)

The liposome of claim 1, wherein the one or more lysolipids have one C18-C22 acyl group.
